

Christine Oechslein

GMP Focus

Managing Process Validation

A Drugmaker's Guide



Maas & Feith
GMP PUBLISHING



PDF Download

Excerpt from the GMP Compliance Adviser

Bibliographic Data of the Deutsche Nationalbibliothek: <http://dnb.ddb.de>

ISBN: 978-3-95807-056-1

Please note: The contents of this reference e-book were developed and compiled with the utmost of care. The publishers, authors and translators do not assume legal responsibility or any liability whatever for any incorrect information and the consequences thereof.

The material has been adapted and edited in collaboration with the FDAnews,
300 N. Washington St., Suite 200, Falls Church, VA 22046-3431.

First edition, 10/2016

© by Maas & Peither AG – GMP Publishing

Karlstrasse 2

79650 Schopfheim

Germany

Phone: +49 7622 66686-70

Fax: +49 7622 66686-77

service@gmp-publishing.com

<http://www.gmp-publishing.com>

This work, including all of its parts, is protected by copyright. Any use beyond the strict limits of copyright law without prior permission of the publishers is strictly prohibited and liable to prosecution. This also applies to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

Managing Process Validation

A Drugmaker's Guide

Table of Contents

Introduction

Defining Process Validation 4

Who Must Perform Validation? 4

What Faults Can Occur During Validation? 4

Process Validation Approaches 6

Prospective Validation 6

Retrospective Validation..... 6

Concurrent Validation 8

Validation Responsibilities and Assignments 10

Validation Manager..... 10

Outsourcing of Validation Activities 11

Validation Team 12

Validation Planning..... 15

Determining the Scope and Extent of Validation..... 15

Carrying Out Risk Analysis..... 15

Validation Master Plan 17

Validation Prerequisites 18

Product and Process..... 18

Critical Process Parameters and Normal Operating Ranges 19

Qualification and Calibration..... 20

Computer Validation 20

Test Procedure and Analytical Methods..... 20

Cleaning Procedures and Cleaning Validation..... 20

GMP-Compliant General Conditions..... 21

Information Flow 21

What Action Should Be Taken If Not All Prerequisites Have Yet Been Fulfilled? 21

Validation Protocol 22

Determination of the Validation Batches 23

Process Description..... 23

Product Specifications and Quality Attributes.....	24
Quality of Raw Materials Used	24
Facilities and Equipment Used	25
Risk Analysis	25
Critical Processing Steps and Process Parameters.....	25
Test Plans	26
Acceptance Criteria.....	26
Sampling Plan	27
Techniques for Interpretation of the Test Results.....	28
Reference Documents.....	29
Equipment Qualification and Method Validation	29
Changes to the Validation Protocol.....	29
Departments Involved in the Validation and Time Schedule.....	29
Authorization of the Validation Protocol	29
Validation Matrix.....	31
Formation of Product Families or Product Groups	31
Documenting Process Validation	33
Chronology of Document Creation.....	33
Archiving of the Validation Documents	34
Validation Report	35
Batch Production Records.....	35
Test Results.....	35
Raw Data	35
Traceability Matrix.....	36
Deviations from the Validation Protocol	36
Evaluation of the Results	36
Determination of Follow-Up Measures	36
Authorization of the Validation Report	36
How to Deal with Deviations from the Validation Protocol.....	37
Appendices.....	38
A. EU GMP Guidelines, Part 1, Chapter 1 – Pharmaceutical Quality Systems	
B. FDA Guidance on Process Validation: General Principles and Practices	
C. EU GMP Guidelines, Annex 15 – Qualification and Validation	
D. ICH Q9 – Quality Risk Management	
E. Sample Validation Master Plan	
F. Sample Validation Matrix	

Introduction

Validation is a key element of the quality management system in a pharmaceutical company. For a long time, our understanding of pharmaceutical quality was such that one relied solely on the control of raw materials and final products. The intermediate process was guaranteed by established experience and the professional honesty of longtime employees.

Today, our understanding is almost the reverse. Well-tested raw materials from qualified suppliers are used in a process that must be so well controlled that, theoretically, absolutely nothing can result other than a product that conforms to the specifications. In contrast, the place of manufacture and staff carrying out production are interchangeable, as long as they are qualified.

Validation has thus become a basic component of the quality assurance system of pharmaceutical companies and their suppliers. This development is logical and appropriate not only in terms of pharmacovigilance, but also as regards economic aspects, because when serious quality defects are detected in the final product control, irreparable damage will already have been incurred.

Also because modern active ingredients and novel preparations are becoming ever more costly, rejection of the end product must be avoided by means of preventive measures such as validation. The assessment of a process in the context of validation is also important because the increasingly shorter periods people remain at a company and widespread job rotation prevent them from building up a body of experience and thus also prevent the continuity of information and quality.

Furthermore, in international pharmaceutical companies, production processes are frequently switched between different production sites. In order to guarantee reproducible quality in spite of this, processes must be validated.

Therefore, quality in a product is spoken of in terms of being “*produced* into” and not simply “*tested* into.” Quality is the sum of properties of a product, not only those that are covered in the specifications.

This report looks at the significance of process validation in drug manufacturing and discusses different approaches to validation. It also provides guidance on managing validation efforts, including developing a master plan, protocol and documentation.

About the Author

Christine Oechslein is a 27-year veteran of the pharmaceutical industry, working primarily with Sandoz and Novartis. Over the course of her career, she has developed oral drug delivery systems, headed a lab for development of nasal and pulmonary dosage forms, and helped create a quality manual for Rx development.

Defining Process Validation

Process validation is only a part of a broad concept that includes qualification of equipment, facilities, computers, buildings, building and utility services engineering, staff and suppliers, and demands systematic documentation, archiving and change control.

When the definitions used by different regulatory agencies are compared, it is apparent that the term “validation” is interpreted in very different ways. According to the EU GMP Guidelines Part I, Chapter 1, *Pharmaceutical Quality Systems* (see Appendix A), validation comprises not only processes, but also equipment and materials – the term is thus used as a generic term and also includes qualification. By contrast, the FDA *guidance Process Validation: General Principles and Practices* (see Appendix B) extends the content of process validation to make it a superordinate term which incorporates not only process design in the development phase, but also plant qualification and continuous process verification during routine production.

This relative lack of precision and insufficient demarcation of the terms is found in many places in the international guidelines on the subjects of validation and qualification. Therefore, every company that addresses this group of topics must initially specify its own definition. It is best to regulate such fundamental aspects in the validation master plan (VMP) primarily so a common starting point will exist for smooth communication during the validation activities – both internally and to the outside (contract acceptor, contract giver, authorities).

Who Must Perform Validation?

The demand for validation is no longer restricted solely to pharmaceutical companies, but also to their suppliers, especially the producers of active ingredients, excipients, packaging materials, plants and equipment, including computers.

However, drug manufacturers are responsible, under GMP standards, for ensuring that they work only with qualified plants and only use materials which are produced, packed and stored in accordance with GMP. For some of these, product standards have already been established (e.g., ISO 15378: *GMP for Primary Packaging Materials*) that represent the state of the art – so one should only deviate from them for a good reason.

In all other cases “how much GMP” and “how much validation” a pharmaceutical manufacturer expects from its supplier is a matter of intensive individual discussions and precise contractual agreements, which can differ greatly from product to product and from process to process.

What Faults Can Occur During Validation?

Validation is regularly subject to inspections, be it by customers or by the public authorities responsible.

Numerous shortcomings are still detected here: about 10% of all GMP complaints are connected with validations – thus occupying one of the top places in the “hit list” of all GMP defects!

Typical faults include:

- Validation plans are not created or not complied with;
- Details about the equipment used, critical process parameters, sampling data, number of validation batches or acceptance criteria are missing;
- Changes to validated processes are not included or not included properly;
- Deviations while validation is being performed are not documented, examined or commented on, or this is not done properly;
- No rationale for acceptance criteria is documented;
- Validation reports do not reflect the specifications from the validation plan, for example, reports contain acceptance criteria which were not specified in the validation plan;
- No risk-based approach is recognizable, i.e. the scope of the validation activities was not defined by means of quality risk analyses.